PF-02341066 (crizotinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-02341066 (crizotinib), covering 2016-06-09 to 2016-06-09. Get the full timeline:
Most recent: Clinical Trial Update: An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene [Phase 2]